Novartis AG $NVS Holdings Reduced by BXM Wealth LLC

Posted by George Bondi on Jun 30th, 2026

BXM Wealth LLC lowered its position in Novartis AG (NYSE:NVS – Free Report) by 88.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 4,840 shares of the company’s stock after selling 37,977 shares during the quarter. BXM Wealth LLC’s holdings in Novartis were worth $739,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Auto Owners Insurance Co boosted its position in shares of Novartis by 13,687.0% during the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock worth $638,103,000 after buying an additional 4,594,726 shares during the period. Morgan Stanley increased its position in Novartis by 14.9% in the 4th quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock valued at $1,223,860,000 after acquiring an additional 1,148,033 shares during the period. GQG Partners LLC raised its stake in Novartis by 39.6% during the 4th quarter. GQG Partners LLC now owns 3,158,122 shares of the company’s stock valued at $435,414,000 after acquiring an additional 895,255 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Novartis during the 4th quarter valued at $108,638,000. Finally, Raymond James Financial Inc. boosted its position in Novartis by 77.7% during the 3rd quarter. Raymond James Financial Inc. now owns 1,648,174 shares of the company’s stock worth $211,362,000 after acquiring an additional 720,860 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Up 1.4%

Shares of NVS stock opened at $157.56 on Tuesday. Novartis AG has a 1 year low of $112.34 and a 1 year high of $170.46. The stock has a market cap of $300.66 billion, a PE ratio of 22.57, a price-to-earnings-growth ratio of 2.74 and a beta of 0.46. The business’s fifty day moving average is $149.20 and its 200-day moving average is $149.83. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85.

Novartis (NYSE:NVS – Get Free Report) last posted its quarterly earnings data on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). The firm had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.28 EPS. Equities analysts expect that Novartis AG will post 8.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on NVS. Argus raised Novartis from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a research note on Wednesday, March 11th. Sanford C. Bernstein upgraded shares of Novartis to a “hold” rating in a research note on Thursday, March 19th. Weiss Ratings downgraded shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Finally, Morgan Stanley increased their target price on shares of Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research report on Thursday, March 26th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Novartis has a consensus rating of “Hold” and an average target price of $141.20.

Check Out Our Latest Stock Analysis on NVS

About Novartis

(Free Report)

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.

Novartis AG $NVS Holdings Reduced by BXM Wealth LLC

Novartis Stock Up 1.4%

Analyst Upgrades and Downgrades

About Novartis

Further Reading

You might be interested in: